Pflügers Archiv - European Journal of Physiology

, Volume 465, Issue 1, pp 167–175 | Cite as

Metabolic rate regulation by the renin–angiotensin system: brain vs. body

  • Justin L. Grobe
  • Kamal Rahmouni
  • Xuebo Liu
  • Curt D. Sigmund
Invited Review

Abstract

Substantial evidence supports a role for the renin–angiotensin system (RAS) in the regulation of metabolic function, but an apparent paradox exists where genetic or pharmacological inhibition of the RAS occasionally has similar physiological effects as chronic angiotensin infusion. Similarly, while RAS targeting in animal models has robust metabolic consequences, effects in humans are more subtle. Here, we review the data supporting a role for the RAS in metabolic rate regulation and propose a model where the local brain RAS works in opposition to the peripheral RAS, thus helping to explain the paradoxically similar effects of RAS supplementation and inhibition. Selectively modulating the peripheral RAS or brain RAS may thus provide a more effective treatment paradigm for obesity and obesity-related disorders.

Keywords

Obesity Metabolism Energy homeostasis Thermogenesis 

References

  1. 1.
    Achard V, Boullu-Ciocca S, Desbriere R, Nguyen G, Grino M (2007) Renin receptor expression in human adipose tissue. Am J Physiol Regul Integr Comp Physiol 292:R274–R282PubMedCrossRefGoogle Scholar
  2. 2.
    Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH (1991) Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 324:1098–1104PubMedCrossRefGoogle Scholar
  3. 3.
    Alligier M, Meugnier E, Debard C, Lambert-Porcheron S, Chanseaume E, Sothier M, Loizon E, Ait HA, Brozek J, Scoazec JY, Morio B, Vidal H, Laville M (2011) Subcutaneous adipose tissue remodeling during the initial phase of weight gain induced by overfeeding in humans. J Clin Endocrinol Metab 97:E183–E192PubMedCrossRefGoogle Scholar
  4. 4.
    American Diabates Association (2008) Economic costs of diabetes in the U.S. in 2007. Diabetes Care 31:596–615CrossRefGoogle Scholar
  5. 5.
    Bernstein AM, Willett WC (2010) Trends in 24-h urinary sodium excretion in the United States, 1957–2003: a systematic review. Am J Clin Nutr 92:1172–1180PubMedCrossRefGoogle Scholar
  6. 6.
    Bloem LJ, Manatunga AK, Tewksbury DA, Pratt JH (1995) The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children. J Clin Invest 95:948–953PubMedCrossRefGoogle Scholar
  7. 7.
    Boschmann M, Ringel J, Klaus S, Sharma AM (2001) Metabolic and hemodynamic response of adipose tissue to angiotensin II. Obes Res 9:486–491PubMedCrossRefGoogle Scholar
  8. 8.
    Brink M, Price SR, Chrast J, Bailey JL, Anwar A, Mitch WE, Delafontaine P (2001) Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. Endocrinology 142:1489–1496PubMedCrossRefGoogle Scholar
  9. 9.
    Carman WJ, Barrett-Connor E, Sowers M, Khaw KT (1994) Higher risk of cardiovascular mortality among lean hypertensive individuals in Tecumseh, Michigan. Circulation 89:703–711PubMedCrossRefGoogle Scholar
  10. 10.
    Carter CS, Cesari M, Ambrosius WT, Hu N, Diz D, Oden S, Sonntag WE, Pahor M (2004) Angiotensin-converting enzyme inhibition, body composition, and physical performance in aged rats. J Gerontol A Biol Sci Med Sci 59:416–423PubMedCrossRefGoogle Scholar
  11. 11.
    Cassis LA, Dwoskin LP (1991) Presynaptic modulation of neurotransmitter release by endogenous angiotensin II in brown adipose tissue. J Neural Transm Suppl 34:129–137PubMedGoogle Scholar
  12. 12.
    Cassis L, Helton M, English V, Burke G (2002) Angiotensin II regulates oxygen consumption. Am J Physiol Regul Integr Comp Physiol 282:R445–R453PubMedGoogle Scholar
  13. 13.
    Chou CL, Lai YH, Lin TY, Lee TJ, Fang TC (2011) Aliskiren prevents and ameliorates metabolic syndrome in fructose-fed rats. Arch Med Sci 7:882–888PubMedCrossRefGoogle Scholar
  14. 14.
    Cole BK, Keller SR, Wu R, Carter JD, Nadler JL, Nunemaker CS (2010) Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice. Hypertension 55:715–721PubMedCrossRefGoogle Scholar
  15. 15.
    Cooper R, McFarlane-Anderson N, Bennett FI, Wilks R, Puras A, Tewksbury D, Ward R, Forrester T (1997) ACE, angiotensinogen and obesity: a potential pathway leading to hypertension. J Hum Hypertens 11:107–111PubMedCrossRefGoogle Scholar
  16. 16.
    Crandall DL, Armellino DC, Busler DE, McHendry-Rinde B, Kral JG (1999) Angiotensin II receptors in human preadipocytes: role in cell cycle regulation. Endocrinology 140:154–158PubMedCrossRefGoogle Scholar
  17. 17.
    Darimont C, Vassaux G, Ailhaud G, Negrel R (1994) Differentiation of preadipose cells: paracrine role of prostacyclin upon stimulation of adipose cells by angiotensin-II. Endocrinology 135:2030–2036PubMedCrossRefGoogle Scholar
  18. 18.
    de Kloet AD, Krause EG, Scott KA, Foster MT, Herman JP, Sakai RR, Seeley RJ, Woods SC (2011) Central angiotensin II has catabolic action at white and brown adipose tissue. Am J Physiol Endocrinol Metab 301:E1081–E1091PubMedCrossRefGoogle Scholar
  19. 19.
    Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM (2005) Weight loss and the renin-angiotensin-aldosterone system. Hypertension 45:356–362PubMedCrossRefGoogle Scholar
  20. 20.
    English V, Cassis L (1999) Facilitation of sympathetic neurotransmission contributes to angiotensin regulation of body weight. J Neural Transm 106:631–644PubMedCrossRefGoogle Scholar
  21. 21.
    Ernsberger P, Koletsky RJ (2006) Metabolic effects of antihypertensive agents: role of sympathoadrenal and renin-angiotensin systems. Naunyn Schmiedebergs Arch Pharmacol 373:245–258PubMedCrossRefGoogle Scholar
  22. 22.
    Faloia E, Gatti C, Camilloni MA, Mariniello B, Sardu C, Garrapa GG, Mantero F, Giacchetti G (2002) Comparison of circulating and local adipose tissue renin-angiotensin system in normotensive and hypertensive obese subjects. J Endocrinol Invest 25:309–314PubMedGoogle Scholar
  23. 23.
    Ferguson AV, Washburn DL, Latchford KJ (2001) Hormonal and neurotransmitter roles for angiotensin in the regulation of central autonomic function. Exp Biol Med (Maywood) 226:85–96Google Scholar
  24. 24.
    Flegal KM, Graubard BI, Williamson DF, Gail MH (2005) Excess deaths associated with underweight, overweight, and obesity. JAMA 293:1861–1867PubMedCrossRefGoogle Scholar
  25. 25.
    Fleming I, Kohlstedt K, Busse R (2006) The tissue renin-angiotensin system and intracellular signalling. Curr Opin Nephrol Hypertens 15:8–13PubMedCrossRefGoogle Scholar
  26. 26.
    Fowler JD, Krueth SB, Bernlohr DA, Katz SA (2009) Renin dynamics in adipose tissue: adipose tissue control of local renin concentrations. Am J Physiol Endocrinol Metab 296:E343–E350PubMedCrossRefGoogle Scholar
  27. 27.
    Galvez-Prieto B, Bolbrinker J, Stucchi P, de Las Heras AI, Merino B, Arribas S, Ruiz-Gayo M, Huber M, Wehland M, Kreutz R, Fernandez-Alfonso MS (2008) Comparative expression analysis of the renin-angiotensin system components between white and brown perivascular adipose tissue. J Endocrinol 197:55–64PubMedCrossRefGoogle Scholar
  28. 28.
    Giacchetti G, Faloia E, Mariniello B, Sardu C, Gatti C, Camilloni MA, Guerrieri M, Mantero F (2002) Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am J Hypertens 15:381–388PubMedCrossRefGoogle Scholar
  29. 29.
    Goossens GH, Blaak EE, van Baak MA (2003) Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev 4:43–55PubMedCrossRefGoogle Scholar
  30. 30.
    Gratze P, Boschmann M, Dechend R, Qadri F, Malchow J, Graeske S, Engeli S, Janke J, Springer J, Contrepas A, Plehm R, Klaus S, Nguyen G, Luft FC, Muller DN (2009) Energy metabolism in human renin-gene transgenic rats: does renin contribute to obesity? Hypertension 53:516–523PubMedCrossRefGoogle Scholar
  31. 31.
    Grobe JL, Buehrer BA, Hilzendeger AM, Liu X, Davis DR, Xu D, Sigmund CD (2011) Angiotensinergic signaling in the brain mediates metabolic effects of deoxycorticosterone (DOCA)-salt in C57 mice. Hypertension 57:600–607PubMedCrossRefGoogle Scholar
  32. 32.
    Grobe JL, Grobe CL, Beltz TG, Westphal SG, Morgan DA, Xu D, de Lange WJ, Li H, Sakai K, Thedens DR, Cassis LA, Rahmouni K, Mark AL, Johnson AK, Sigmund CD (2010) The brain renin-angiotensin system controls divergent efferent mechanisms to regulate fluid and energy balance. Cell Metab 12:431–442PubMedCrossRefGoogle Scholar
  33. 33.
    Grobe JL, Xu D, Sigmund CD (2008) An intracellular renin-angiotensin system in neurons: fact, hypothesis, or fantasy. Physiology (Bethesda) 23:187–193CrossRefGoogle Scholar
  34. 34.
    Hammond RA, LeVine R (2010) The economic impact of obesity in the United States. Diabetes Metab Syndr Obes 3:285–295PubMedCrossRefGoogle Scholar
  35. 35.
    Idelevich E, Kirch W, Schindler C (2009) Current pharmacotherapeutic concepts for the treatment of obesity in adults. Ther Adv Cardiovasc Dis 3:75–90PubMedCrossRefGoogle Scholar
  36. 36.
    Itaya Y, Suzuki H, Matsukawa S, Kondo K, Saruta T (1986) Central renin-angiotensin system and the pathogenesis of DOCA-salt hypertension in rats. Am J Physiol 251:H261–H268PubMedGoogle Scholar
  37. 37.
    Iwai M, Tomono Y, Inaba S, Kanno H, Senba I, Mogi M, Horiuchi M (2009) AT2 receptor deficiency attenuates adipocyte differentiation and decreases adipocyte number in atherosclerotic mice. Am J Hypertens 22:784–791PubMedCrossRefGoogle Scholar
  38. 38.
    Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM (2002) Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 51:1699–1707PubMedCrossRefGoogle Scholar
  39. 39.
    Jayasooriya AP, Mathai ML, Walker LL, Begg DP, Denton DA, Cameron-Smith D, Egan GF, McKinley MJ, Rodger PD, Sinclair AJ, Wark JD, Weisinger HS, Jois M, Weisinger RS (2008) Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance. Proc Natl Acad Sci USA 105:6531–6536PubMedCrossRefGoogle Scholar
  40. 40.
    Karlsson C, Lindell K, Ottosson M, Sjostrom L, Carlsson B, Carlsson LM (1998) Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab 83:3925–3929PubMedCrossRefGoogle Scholar
  41. 41.
    Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548–2556PubMedCrossRefGoogle Scholar
  42. 42.
    Kouyama R, Suganami T, Nishida J, Tanaka M, Toyoda T, Kiso M, Chiwata T, Miyamoto Y, Yoshimasa Y, Fukamizu A, Horiuchi M, Hirata Y, Ogawa Y (2005) Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Endocrinology 146:3481–3489PubMedCrossRefGoogle Scholar
  43. 43.
    Krysiak R, Sierant M, Marek B, Bienek R, Okopien B (2010) The effect of angiotensin-converting enzyme inhibitors on plasma adipokine levels in normotensive patients with coronary artery disease. Endokrynol Pol 61:280–287PubMedGoogle Scholar
  44. 44.
    Kubo T, Yamaguchi H, Tsujimura M, Hagiwara Y, Fukumori R (2000) Blockade of angiotensin receptors in the anterior hypothalamic preoptic area lowers blood pressure in DOCA-salt hypertensive rats. Hypertens Res 23:109–118PubMedCrossRefGoogle Scholar
  45. 45.
    Lavoie JL, Sigmund CD (2003) Minireview: overview of the renin-angiotensin system–an endocrine and paracrine system. Endocrinology 144:2179–2183PubMedCrossRefGoogle Scholar
  46. 46.
    Lee-Kirsch MA, Gaudet F, Cardoso MC, Lindpaintner K (1999) Distinct renin isoforms generated by tissue-specific transcription initiation and alternative splicing. Circ Res 84:240–246PubMedCrossRefGoogle Scholar
  47. 47.
    Massiera F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc JM, Quignard-Boulange A, Negrel R, Ailhaud G, Seydoux J, Meneton P, Teboul M (2001) Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 15:2727–2729PubMedGoogle Scholar
  48. 48.
    Massiera F, Seydoux J, Geloen A, Quignard-Boulange A, Turban S, Saint-Marc P, Fukamizu A, Negrel R, Ailhaud G, Teboul M (2001) Angiotensinogen-deficient mice exhibit impairment of diet induced weight gain with alteration in adipose tissue development and increased locomotor activity. Endocrinology 142:5220–5225PubMedCrossRefGoogle Scholar
  49. 49.
    Masuo K, Mikami H, Ogihara T, Tuck ML (2001) Weight reduction and pharmacologic treatment in obese hypertensives. Am J Hypertens 14:530–538PubMedCrossRefGoogle Scholar
  50. 50.
    Mathai ML, Chen N, Cornall L, Weisinger RS (2011) The role of angiotensin in obesity and metabolic disease. Endocr Metab Immune Disord Drug Targets 11:198–205PubMedCrossRefGoogle Scholar
  51. 51.
    Mathai ML, Naik S, Sinclair AJ, Weisinger HS, Weisinger RS (2008) Selective reduction in body fat mass and plasma leptin induced by angiotensin-converting enzyme inhibition in rats. Int J Obes (Lond) 32:1576–1584CrossRefGoogle Scholar
  52. 52.
    Matsushita K, Wu Y, Okamoto Y, Pratt RE, Dzau VJ (2006) Local renin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes. Hypertension 48:1095–1102PubMedCrossRefGoogle Scholar
  53. 53.
    McClendon KS, Riche DM, Uwaifo GI (2009) Orlistat: current status in clinical therapeutics. Expert Opin Drug Saf 8:727–744PubMedGoogle Scholar
  54. 54.
    Messerli FH, Nunez BD, Ventura HO, Snyder DW (1987) Overweight and sudden death. Increased ventricular ectopy in cardiopathy of obesity. Arch Int Med 147:1725–1728CrossRefGoogle Scholar
  55. 55.
    Mogi M, Iwai M, Horiuchi M (2006) Emerging concept of adipogenesis regulation by the renin-angiotensin system. Hypertension 48:1020–1022PubMedCrossRefGoogle Scholar
  56. 56.
    Morimoto S, Cassell MD, Sigmund CD (2002) Glial- and neuronal-specific expression of the renin-angiotensin system in brain alters blood pressure, water intake, and salt preference. J Biol Chem 277:33235–33241PubMedCrossRefGoogle Scholar
  57. 57.
    Morrison SF, Nakamura K, Madden CJ (2008) Central control of thermogenesis in mammals. Exp Physiol 93:773–797PubMedCrossRefGoogle Scholar
  58. 58.
    Park CG, Leenen FH (2001) Effects of centrally administered losartan on deoxycorticosterone-salt hypertension rats. J Korean Med Sci 16:553–557PubMedGoogle Scholar
  59. 59.
    Porter JP, Anderson JM, Robison RJ, Phillips AC (2003) Effect of central angiotensin II on body weight gain in young rats. Brain Res 959:20–28PubMedCrossRefGoogle Scholar
  60. 60.
    Porter JP, Potratz KR (2004) Effect of intracerebroventricular angiotensin II on body weight and food intake in adult rats. Am J Physiol Regul Integr Comp Physiol 287:R422–R428PubMedCrossRefGoogle Scholar
  61. 61.
    Sakai K, Agassandian K, Morimoto S, Sinnayah P, Cassell MD, Davisson RL, Sigmund CD (2007) Local production of angiotensin II in the subfornical organ causes elevated drinking. J Clin Invest 117:1088–1095PubMedCrossRefGoogle Scholar
  62. 62.
    Santos EL, de Picoli SK, Guimaraes PB, Reis FC, Silva SM, Costa-Neto CM, Luz J, Pesquero JB (2008) Effect of angiotensin converting enzyme inhibitor enalapril on body weight and composition in young rats. Int Immunopharmacol 8:247–253PubMedCrossRefGoogle Scholar
  63. 63.
    Santos SH, Fernandes LR, Mario EG, Ferreira AV, Porto LC, Alvarez-Leite JI, Botion LM, Bader M, Alenina N, Santos RA (2008) Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes 57:340–347PubMedCrossRefGoogle Scholar
  64. 64.
    Satin M (2011) The salt debate–more salacious than salubrious. Nutrition 27:759–760PubMedCrossRefGoogle Scholar
  65. 65.
    Saye JA, Ragsdale NV, Carey RM, Peach MJ (1993) Localization of angiotensin peptide-forming enzymes of 3T3-F442A adipocytes. Am J Physiol 264:C1570–C1576PubMedGoogle Scholar
  66. 66.
    Sinn PL, Sigmund CD (2000) Identification of three human renin mRNA isoforms from alternative tissue-specific transcriptional initiation. Physiol Genom 3:25–31Google Scholar
  67. 67.
    Stec DE, Davisson RL, Haskell RE, Davidson BL, Sigmund CD (1999) Efficient liver-specific deletion of a floxed human angiotensinogen transgene by adenoviral delivery of cre-recombinase in vivo. J Biol Chem 274:21285–21290PubMedCrossRefGoogle Scholar
  68. 68.
    Stec DE, Keen HL, Sigmund CD (2002) Lower blood pressure in floxed angiotensinogen mice after adenoviral delivery of cre-recombinase. Hypertension 39:629–633PubMedCrossRefGoogle Scholar
  69. 69.
    Stucchi P, Cano V, Ruiz-Gayo M, Fernandez-Alfonso MS (2009) Aliskiren reduces body-weight gain, adiposity and plasma leptin during diet-induced obesity. Br J Pharmacol 158:771–778PubMedCrossRefGoogle Scholar
  70. 70.
    Sui Y, Zhao HL, Fan RR, Guan J, He L, Lee HM, Chan JC, Tong PC (2010) Renin-angiotensin system activation in renal adipogenesis. Am J Physiol Renal Physiol 298:F391–F400PubMedCrossRefGoogle Scholar
  71. 71.
    Takahashi N, Li F, Hua K, Deng J, Wang CH, Bowers RR, Bartness TJ, Kim HS, Harp JB (2007) Increased energy expenditure, dietary fat wasting, and resistance to diet-induced obesity in mice lacking renin. Cell Metab 6:506–512PubMedCrossRefGoogle Scholar
  72. 72.
    Thatcher S, Yiannikouris F, Gupte M, Cassis L (2009) The adipose renin-angiotensin system: role in cardiovascular disease. Mol Cell Endocrinol 302:111–117PubMedCrossRefGoogle Scholar
  73. 73.
    Vetter ML, Faulconbridge LF, Webb VL, Wadden TA (2010) Behavioral and pharmacologic therapies for obesity. Nat Rev Endocrinol 6:578–588PubMedGoogle Scholar
  74. 74.
    Wang P, Holst C, Wodzig WK, Andersen MR, Astrup A, van Baak MA, Larsen TM, Jebb SA, Kafatos A, Pfeiffer AF, Martinez JA, Handjieva-Darlenska T, Kunesova M, Viguerie N, Langin D, Saris WH, Mariman EC (2012) Circulating ACE is a predictor of weight loss maintenance not only in overweight and obese women, but also in men. Int J Obes (Lond) (in press)Google Scholar
  75. 75.
    Weiland F, Verspohl EJ (2008) Variety of angiotensin receptors in 3T3-L1 preadipose cells and differentiated adipocytes. Horm Metab Res 40:760–766PubMedCrossRefGoogle Scholar
  76. 76.
    Weisinger RS, Stanley TK, Begg DP, Weisinger HS, Spark KJ, Jois M (2009) Angiotensin converting enzyme inhibition lowers body weight and improves glucose tolerance in C57BL/6J mice maintained on a high fat diet. Physiol Behav 98:192–197PubMedCrossRefGoogle Scholar
  77. 77.
    Xu D, Borges GR, Davis DR, Agassandian K, Sequeira Lopez ML, Gomez RA, Cassell MD, Grobe JL, Sigmund CD (2011) Neuron- or glial-specific ablation of secreted renin does not affect renal renin, baseline arterial pressure or metabolism. Physiol Genom 43:286–294CrossRefGoogle Scholar
  78. 78.
    Xu D, Borges GR, Grobe JL, Pelham CJ, Yang B, Sigmund CD (2009) Preservation of intracellular renin expression is insufficient to compensate for genetic loss of secreted renin. Hypertension 54:1240–1247PubMedCrossRefGoogle Scholar
  79. 79.
    Yang G, Merrill DC, Thompson MW, Robillard JE, Sigmund CD (1994) Functional expression of the human angiotensinogen gene in transgenic mice. J Biol Chem 269:32497–32502PubMedGoogle Scholar
  80. 80.
    Yiannikouris F, Karounos M, Charnigo R, English VL, Rateri DL, Daugherty A, Cassis LA (2012) Adipocyte-specific deficiency of angiotensinogen decreases plasma angiotensinogen concentration and systolic blood pressure in mice. Am J Physiol Regul Integr Comp Physiol 302:R244–R251PubMedCrossRefGoogle Scholar
  81. 81.
    Yoshida T, Semprun-Prieto L, Wainford RD, Sukhanov S, Kapusta DR, Delafontaine P (2012) Angiotensin II reduces food intake by altering orexigenic neuropeptide expression in the mouse hypothalamus. Endocrinology. doi:10.1210/en.2011-1764
  82. 82.
    Yvan-Charvet L, Even P, Bloch-Faure M, Guerre-Millo M, Moustaid-Moussa N, Ferre P, Quignard-Boulange A (2005) Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes 54:991–999PubMedCrossRefGoogle Scholar
  83. 83.
    Yvan-Charvet L, Massiera F, Lamande N, Ailhaud G, Teboul M, Moustaid-Moussa N, Gasc JM, Quignard-Boulange A (2009) Deficiency of angiotensin type 2 receptor rescues obesity but not hypertension induced by overexpression of angiotensinogen in adipose tissue. Endocrinology 150:1421–1428PubMedCrossRefGoogle Scholar
  84. 84.
    Yvan-Charvet L, Quignard-Boulange A (2011) Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity. Kidney Int 79:162–168PubMedCrossRefGoogle Scholar
  85. 85.
    Zanchi A, Dulloo AG, Perregaux C, Montani JP, Burnier M (2007) Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties. Am J Physiol Endocrinol Metab 293:E91–E95PubMedCrossRefGoogle Scholar
  86. 86.
    Zorad S, Dou JT, Benicky J, Hutanu D, Tybitanclova K, Zhou J, Saavedra JM (2006) Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma. Eur J Pharmacol 552:112–122PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Justin L. Grobe
    • 1
  • Kamal Rahmouni
    • 1
  • Xuebo Liu
    • 1
  • Curt D. Sigmund
    • 1
  1. 1.Department of Pharmacology, Roy J. and Lucille A. Carver College of MedicineUniversity of IowaIowa CityUSA

Personalised recommendations